AMO viscoelastic gains FDA approval

Article

Healon D latex-free viscoelastic (AMO) has been granted premarket approval by the FDA. The clear dispersive ophthalmic viscosurgical device (OVD) is designed to be used during phacoemulsification, intraocular lens (IOL) implantation, keratoplasty and glaucoma filtration surgery.

Healon D latex-free viscoelastic (AMO) has been granted premarket approval by the FDA. The clear dispersive ophthalmic viscosurgical device (OVD) is designed to be used during phacoemulsification, intraocular lens (IOL) implantation, keratoplasty and glaucoma filtration surgery.

Healon D has low viscosity and low molecular weight, allowing it to provide lubrication for IOL insertion and to remain coating the cornea throughout surgery, thereby providing endothelial cell protection. Healon D will be available in dual-packs with either standard Healon, or with Healon GV, an existing AMO OVD, which has a high viscosity and high molecular weight.

The packs containing Healon D will be available before the end of the year.

Recent Videos
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.